Homosalate Safety: High Absorption, Shrinking Limits
Last updated September 22, 2026
Filters UVB only, and the EU has already cut how much of it a product may contain.
Homosalate (3,3,5-trimethylcyclohexyl salicylate) is a widely used UVB filter found in most chemical sunscreens. While providing moderate UVB protection, it demonstrates concerning systemic absorption and may act as a penetration enhancer for other ingredients.
Is Homosalate Safe? The Short Answer
Homosalate is one of three common filters — with oxybenzone and octocrylene — that the EU has restricted on safety grounds since 2022, and the one cut hardest. It is still legal everywhere it was legal before, but in the EU the ceiling fell from 10% to 7.34% (a cut of about 27%) and the permission now covers face products only. Against the US limit of 15%, that is less than half.
- European Union — limit cut from 10% to 7.34%, face products only. Its safety committee concluded in June 2021 that homosalate is not safe as a UV filter at concentrations up to 10%. Industry then re-calculated the margin of safety for face products alone, and per recital 11 of the resulting regulation the committee "issued scientific advice on 2 December 2021, where it concluded that Homosalate is safe as a UV-filter at concentrations up to 7,34 % when used in face products in the form of cream and pump spray." Regulation (EU) 2022/2195 wrote that into law: non-compliant products could not be placed on the EU market from 1 January 2025, nor made available from 1 July 2025.
- Australia — reduction recommended. The TGA's 2025 review of seven sunscreen actives recommended restricting homosalate, mirroring the EU.
- United States — 15% still permitted, safety undetermined. The FDA has proposed Category III for homosalate: "The public record does not contain sufficient data to support a positive GRASE determination for … homosalate … at this time." That proposal has never been finalized.
What drove the EU reassessment was not an observed harm in people, and not the FDA's plasma measurements either. Homosalate was placed on the Commission's 2019 priority list over potential endocrine-disrupting properties, and the committee's problem with 10% was arithmetic: at that concentration the calculated margin of safety fell below 100, the threshold the EU treats as adequate. Restricting the filter to face products cut the modelled exposure enough to bring the margin back above it.
The US picture is the separate one. The FDA's maximal-use trial measured homosalate in plasma at 23.1 ng/mL from an aerosol spray after four days of heavy application — 46 times the 0.5 ng/mL threshold — and 7.6 ng/mL, about 15 times it, after a single application. That threshold is not a danger line: it is the level below which the FDA may waive some of the additional safety studies it would otherwise require. Homosalate is also a penetration enhancer, so it can raise exposure to whatever else is in the bottle.
Practical reading: homosalate at the concentrations in a US sunscreen is not a reason to skip sun protection. If you would rather not take the open question, a zinc-oxide mineral sunscreen avoids it entirely.
Chemical Properties and UV Protection
Homosalate is an organic salicylate compound that absorbs UVB radiation in the 295-315 nm range. Approved at concentrations up to 15% in the US and 10% in the EU, it's one of the most commonly used sunscreen ingredients due to its oil solubility and relatively low cost.
UV Absorption Spectrum
With peak absorption at 306 nm, homosalate provides protection primarily against UVB rays responsible for sunburn. However, it offers no UVA protection, requiring combination with other filters for broad-spectrum coverage. Its moderate SPF contribution means high concentrations are needed for adequate protection.
Formulation Properties
Homosalate serves dual purposes in sunscreen formulations:
- Acts as a solvent for other UV filters, particularly avobenzone
- Functions as an emollient, improving product texture
- Enhances penetration of other ingredients through the skin
- Stabilizes formulations due to oil miscibility
Systemic Absorption Research
FDA Absorption Studies (2019-2020)
The FDA's randomized maximal-use trial (Matta et al., JAMA 2020;323:256-267, 48 participants) found homosalate plasma concentrations peaking at 23.1 ng/mL from an aerosol spray, 17.9 ng/mL from a non-aerosol spray and 13.9 ng/mL from a pump spray after four days of application at 2 mg/cm² to 75% of body surface area four times daily - up to 46 times the FDA's 0.5 ng/mL threshold. A single application on day 1 already produced 7.6, 4.6 and 3.8 ng/mL respectively, 15 times the threshold at the top end. The 0.5 ng/mL figure is the level below which the agency may waive some additional nonclinical safety studies, not a level at which harm has been shown.
Key absorption findings:
- Rapidly absorbed through skin within 2 hours of application
- Accumulates in body with repeated use
- Metabolites detected in urine for days after use
- Higher absorption from spray versus lotion formulations
- Acts as penetration enhancer, potentially increasing absorption of other chemicals
Safety Concerns
Endocrine Disruption Potential
Laboratory studies indicate homosalate may interfere with hormone systems:
- Estrogenic activity: Weak estrogen receptor binding observed
- Anti-androgenic effects: May interfere with male hormones
- Progesterone disruption: Affects progesterone receptor signaling
- Metabolic effects: May influence fatty acid metabolism
Breakdown Products
Homosalate breaks down into multiple metabolites, including salicylic acid. These breakdown products may have different toxicological profiles than the parent compound and can accumulate in tissues.
Reproductive Concerns
Animal studies have shown homosalate exposure may affect reproductive organ development and function. While human data is limited, the high absorption rates raise concerns about potential reproductive effects.
Environmental Impact
Homosalate has been detected in:
- Surface waters near beaches and recreational areas
- Wastewater treatment plant effluent
- Fish and other aquatic organisms
- Sediments in coastal areas
While not currently banned like oxybenzone, studies suggest homosalate may bioaccumulate in aquatic food chains and potentially affect marine organisms' endocrine systems.
Regulatory Status
United States: Approved at up to 15% concentration, the limit set by the stayed 1999 sunscreen monograph and carried forward by the CARES Act. FDA's 2019 proposed rule proposed homosalate as Category III — additional data needed — and the 2021 proposed order that replaced that rulemaking proposes requirements "substantively the same" as the 2019 rule, with scientific discussions that "are generally the same." Neither has been finalized, so no GRASE (Generally Recognized As Safe and Effective) determination has been made.
European Union: Maximum 7.34%, and only in face products other than propellant sprays. The Scientific Committee on Consumer Safety advised on 2 December 2021 that homosalate is safe up to 7.34% in face products in cream and pump-spray form; Commission Regulation (EU) 2022/2195 replaced the previous 10% all-products limit with that figure. Non-compliant products could no longer be placed on the EU market from 1 January 2025, or made available from 1 July 2025.
Other regions: Generally approved worldwide, though some countries are reassessing safety in light of absorption data.
Australia: Permitted at up to 15% under TGA regulation (AS/NZS 2604:2021 governs product claims). The TGA's 2025 safety review recommended reducing the permitted concentration, mirroring the EU's earlier reduction.
Canada: Permitted under Health Canada's Primary Sunscreen Monograph as an accepted chemical UV filter.
Penetration Enhancement Concerns
Homosalate's ability to enhance skin penetration raises additional concerns:
- Increased absorption of other filters: May boost systemic exposure to companion ingredients
- Enhanced delivery of preservatives: Could increase exposure to parabens and other additives
- Unintended ingredient absorption: May facilitate penetration of fragrance compounds and other formulation components
- Cumulative exposure: Effect multiplies when used with other penetration enhancers
Products Tested in Scientific Research
Measured in the FDA's maximal-use trial
- Aerosol spray: peak plasma 23.1 ng/mL after 4 days of maximal use, 46x the 0.5 ng/mL threshold (JAMA 2020;323:256-267)
- Non-aerosol spray and pump spray: 17.9 and 13.9 ng/mL, 35x and 27x the threshold (JAMA 2020;323:256-267)
- The trial products were not identified by brand, and the 2019 pilot trial (JAMA 2019;321:2082-2091) did not include homosalate at all
Alternatives and Recommendations
For those concerned about homosalate's absorption and potential effects:
- Mineral sunscreens: Zinc oxide provides broad-spectrum protection without systemic absorption
- Newer organic filters: Where available, filters like Tinosorb M offer better safety profiles
- Lower concentration products: Choose formulations with minimal homosalate content
- Physical barriers: Protective clothing and shade reduce need for chemical filters
Given the high systemic absorption and penetration enhancement properties, individuals may want to limit homosalate exposure, especially in leave-on products used daily. When using homosalate-containing sunscreens, apply sparingly and avoid spray formulations that increase inhalation risk.
Recommended: CeraVe Hydrating Mineral Sunscreen SPF 50 — a homosalate-free mineral alternative
Our Verdict: 2/5
Homosalate is a common UVB filter that provides only moderate protection with no UVA coverage, and shows high systemic absorption (46x the FDA testing threshold after four days of maximal use) plus penetration-enhancing and possible endocrine effects. The EU has cut its permitted concentration; mineral filters are a lower-absorption alternative.
Pros
- Effective UVB absorber at its 306 nm peak, widely available and low cost
- Oil-soluble, so it doubles as a solvent and stabilizer for avobenzone
- Improves product texture as an emollient
Cons
- No UVA protection — needs other filters for broad-spectrum coverage
- FDA found plasma levels 46x the testing threshold after four days of maximal use (15x after one application)
- Acts as a penetration enhancer, potentially increasing absorption of other ingredients
- Weak endocrine activity in lab studies; FDA has not granted GRASE status
Frequently Asked Questions
Is homosalate safe?
Homosalate is one of three common filters — with oxybenzone and octocrylene — that the EU has restricted on safety grounds since 2022, and the one cut hardest. Its safety committee first concluded in June 2021 that homosalate is not safe at concentrations up to 10%; after industry re-ran the exposure maths for face products only, the committee advised in December 2021 that 7.34% in face cream and pump spray is safe, and Regulation (EU) 2022/2195 made that the limit. Australia's TGA recommended a reduction too. The US still permits 15%, and the FDA has proposed Category III for homosalate — the record does not contain enough data to call it safe and effective.
What does homosalate do in sunscreen?
It absorbs UVB radiation, peaking around 306 nm, and it is oil-soluble, so it doubles as a solvent that dissolves and stabilizes other filters such as avobenzone. It gives no UVA protection, so a broad-spectrum product always pairs it with something else.
Is homosalate a chemical sunscreen?
Yes. Homosalate is an organic (carbon-based) UV filter — a salicylate ester — that works by absorbing UV radiation. The mineral filters are zinc oxide and titanium dioxide, which the FDA proposed as GRASE in 2019; the only organic filter it has since found GRASE is bemotrizinol (June 2026).
How much homosalate is allowed in sunscreen?
The US limit is 15%. The EU limit is 7.34%, and only in face products other than propellant sprays — it was 10% across all cosmetics until Regulation (EU) 2022/2195 cut it, with full effect from 1 July 2025. Australia permits up to 15%, though the TGA's 2025 review recommended reducing that.
What are homosalate's side effects?
The concerns on the record are systemic rather than surface-level. The FDA's maximal-use trial measured homosalate in plasma at 23.1 ng/mL after four days of heavy application — 46 times the agency's 0.5 ng/mL testing threshold, and 15 times it after a single application; it acts as a penetration enhancer, which can increase absorption of other ingredients in the same product; and it shows weak endocrine activity in laboratory assays. The FDA says the chronic-exposure and developmental toxicology data needed to interpret those findings do not exist yet.